Navigation Links
Arbor Vita and WRAIR sign CRADA for traumatic brain injury collaboration
Date:9/8/2008

Sunnyvale, CA September 8, 2008 The U.S. Department of Applied Neurobiology at the Walter Reed Army Institute of Research (WRAIR) and Arbor Vita Corporation (AVC) have signed a Cooperative Research and Development Agreement (CRADA) for research and development of treatments for traumatic brain injury (TBI). The alliance is based on discoveries made from a collaborative effort between AVC and NoNO Inc., of Toronto, Canada, and will explore the use of the companies' NA-1 compound as a novel neuroprotective agent for severe brain injury of soldiers and civilians injured in explosions such as roadside bombs. NA-1 is an investigational compound that targets a PDZ protein and is in clinical trials for the treatment of stroke.

Arbor Vita Corporation has a novel drug development strategy targeting the PDZ family of proteins critical elements that organize and regulate many signaling pathways in cells. The disruption of PDZ interactions provides a means to control specific signaling cascades in complex diseases, including that which controls the death of neurons in the brain following a stroke. The combined research approach of WRAIR brain trauma scientists and neuroprotection experts and the neuroscience research teams of AVC and NoNO Inc. will provide a unique opportunity for conducting advanced preclinical neuroprotection research in a model of brain injury that mimics some types of battlefield injuries. The ultimate goal of the program is the advanced development of a novel therapy for the acute treatment of brain injury.

Traumatic brain injuries from bombs and other explosions are troubling consequences of modern urban and terrorist warfare for both military personnel and civilians. Every year, approximately 1,400,000 individuals in the U.S. and upwards of 2,000,000 worldwide experience traumatic brain injuries. To date, despite very encouraging preclinical results, almost all Phase II/III neuroprotection clinical trials for stroke and TBI have failed to show any consistent improvement in outcome for TBI patients. Only therapies that ameliorate blood flow or target secondary effects are in clinical use. There is a clear unmet medical need for such a drug.

The CRADA between the WRAIR and Arbor Vita represents a collaborative effort employing state-of-the-art preclinical research platforms and drug development strategies that may yield a therapeutic agent ready for human clinical trial assessment. Under the terms of the CRADA, Arbor Vita will supply the clinical materials of NA-1 along with supporting preclinical and human clinical research data. WRAIR will conduct a dose-response study to establish proof of efficacy in a variety of brain injury models and, if successful, conduct additional studies in support of Phase II human clinical trials.


'/>"/>

Contact: Debra Bannister
debra.bannister@arborvita.com
530-676-8001
Arbor Vita Corporation
Source:Eurekalert

Related biology news :

1. Heavy metal link to mutations, low growth and fertility among crustaceans in Sydney Harbor tributary
2. Shipwrecks on coral reefs harbor unwanted species
3. Cold Spring Harbor Protocols highlights gene silencing, cancer cell biology methods
4. A field guide to the landscape of Cold Spring Harbor Laboratory
5. Watson-inspired innovation in research at Cold Spring Harbor Laboratory
6. Cold Spring Harbor Protocols features methods for analyzing genomes and plant cells
7. Cold Spring Harbor Protocols features classic approaches for analyzing chromosomes
8. Ugandan monkeys harbor evidence of infection with unknown poxvirus
9. Sydney harbors deadly diet for sea creatures
10. Cold Spring Harbor Laboratory scientists devise potential approach to treat spinal muscular atrophy
11. Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology: